Avalo Therapeutics CFO sells over $1.45 million in stock
At a glance
- $AVTX today−3.26%last $7.13
- Vs industry peers−2.28 pts6-peer median −0.98% · far behind
- Since Aug 25−65.3%from the first trade after the story
- 52-week range9.2% above low$6.53 – $24.27
- Cash runway~12 mo$65.0M cash ÷ $5.5M/mo burn · 10-Q
- In the headline$1.45 millionAmount
- Legal: Filed with SEC
- Clear: key person, regulatory, security, operational, financial integrity
Early signals (1) — filed with the SEC or first reported, not yet widely covered
- Legal · SEC 8-K, Item 1.02, Nov 5: Filed: the termination of a material agreement. View filing →
Close-to-close moves; beta-adjusted against the S&P 500, σ in the stock’s own daily noise; ranges one standard deviation. Reports are outlets’ words or SEC filings. Not a forecast or advice.
What it means
- What to watch: This one turns on a concrete figure ($1.45 million); set it against the recent trend before reading it as a turning point.
- How the stock is trading: $AVTX -3.26% in the latest session.
- Timing: It came out after the closing bell. The session change shown was settled before the story existed, and the next session is the first that could react.
Where the stock stands
Avalo Therapeutics ($AVTX) fell 3.26% to $7.13 in the latest session. Over the past month it is down 38.5%. That leaves it 71% below its 52-week high of $24.27 and 9.2% above its low of $6.53, close to the bottom of its range. It has been a volatile year: the high was 3.7 times the low, so moves this size are not unusual for it.
What the filings say
In its latest report (10-Q, filed Nov 5, 2026), $AVTX lost $18.9M over the quarter to Sep 30, 2026. Operations used $49.2M of cash over the nine months to Sep 30, 2026 — about $5.5M a month — against $65.0M in cash on Sep 30, 2026. At that pace the cash covers about 12 months, which is why financing, asset sales or restructuring tend to come up for companies in this position. Total liabilities were $44.9M against $65.0M of cash on Sep 30, 2026. Its most recent filings before this story: 10-Q on Aug 6, 2026, 8-K on Aug 6, 2026, 8-K on Jun 23, 2026. Figures are as filed with the SEC; the $AVTX page has the full statements.
How much coverage it is getting
This story is more than a month old. Since then Wook has filed one newer story on Avalo Therapeutics in the last 30 days. It reads neutral.
The bigger picture
In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. Health Care reads calm on Wook's supply-chain scanner today, with no unusual stress in the filings and disclosures it watches.
What to watch next
The company's own filings are the primary source. Its latest SEC reports, including any filing on a material event, are on the $AVTX page, and they say what management has disclosed without a reporter in between. Reading how two or three outlets frame the same story is the quickest way to separate the facts from the angle. Wook AI, at the top of the page, can work out how far $AVTX is from its high or compare this week's coverage with earlier weeks.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on August 25, 2026. $AVTX has moved -65.30% ($20.55 to $7.13). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
